Hjem › Tripelnegativ brystkreft › Washington › Seattle
Kliniske studier for Tripelnegativ brystkreft i Seattle, WA
14 studier for Tripelnegativ brystkreft søker deltakere på steder i og rundt Seattle (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekruttererObservasjonsstudie
- Fred Hutchinson Cancer Center, Seattle
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RekruttererFase 3
- Fred Hutchinson Cancer Center ( Site 0042), Seattle
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RekruttererFase 3
- Fred Hutchinson Cancer Center ( Site 0069), Seattle
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RekruttererFase 1/2
- Swedish Medical Center, Seattle
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekruttererFase 1
- University of Washington Fred Hutchinson, Seattle
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- Fred Hutchinson Cancer Center, Seattle
SMP-3124LP in Adults With Advanced Solid Tumors
RekruttererFase 1/2
- University of Washington, Seattle
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruttererFase 1/2
- Swedish Cancer Institute, Seattle
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
RekruttererFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RekruttererFase 1
- University Of Washington, Seattle
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekruttererFase 1/2
- Fred Hutchinson Cancer Center, Seattle
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RekruttererFase 1/2
- Fred Hutch Cancer Center, Seattle
A Study of NX-1607 in Adults With Advanced Malignancies
RekruttererFase 1
- Fred Hutchinson Cancer Center, Seattle
Tripelnegativ brystkreft-studier i andre byer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
Andre studier i Seattle
- Ikke-småcellet lungekreft53 studier
- Kreft (alle typer)49 studier
- Prostatakreft42 studier
- Akut myelogen leukemi41 studier
- Brystkreft39 studier
- Metastatisk kreft39 studier
- Kolorektal kreft34 studier
- Lungekreft33 studier
- Eggstokkreft30 studier
- Multipelt myelom22 studier
- Blærekreft21 studier
- Myelodysplastiske syndromer21 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.